Syndax Pharmaceuticals, Inc.
SNDXDrugs in Pipeline
9
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 5, 2026
18wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Intensive Chemotherapy Regimen
Acute Myeloid Leukemias
Revumenib
Colorectal Cancer
entinostat
Non-Small Cell Lung Cancer
Aromatase Inhibitor (AI) Therapy
ER+ Breast Cancer
avelumab
Epithelial Ovarian Cancer
exemestane
Breast Cancer
cobicistat
Acute Myeloid Leukemia
Axatilimab
Chronic Graft-versus-host-disease
Erlotinib
Non-Small-Cell Lung Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Intensive Chemotherapy Regimen | Phase 3 | Acute Myeloid Leukemias | - | - |
Revumenib | Phase 3 | Colorectal Cancer | - | - |
entinostat | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Aromatase Inhibitor (AI) Therapy | Phase 2 | ER+ Breast Cancer | - | - |
avelumab | Phase 2 | Epithelial Ovarian Cancer | - | - |
exemestane | Phase 2 | Breast Cancer | - | - |
cobicistat | Phase 2 | Acute Myeloid Leukemia | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
Erlotinib | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |